New Radiotherapeutic is Effective and Less Toxic for Neuroendocrine Tumor Patients
MTTI announced today an article entitled “Peptide Receptor Radionuclide Therapy (PRRT) of Late-Stage Neuroendocrine Tumor (NETs) Patients with Multiple Cycles of 177Lu-DOTA-EB-TATE” just published in the March issue of The Journal of Nuclear Medicine.